Astion Pharma Raises EUR 5 Million in New Capital

Astion Pharma A/S has raised EUR 5 million in new capital from its existing shareholders. The new capital will be used to fund its clinical projects and two late-stage preclinical development candidates.

Astion Pharma focuses on developing pharmaceuticals for the treatment of severe skin diseases, and is strengthening its activities in the field of dermatology. It currently has three development projects in Phase II clinical studies for the treatment of hand dermatitis, seborrheic dermatitis and cutaneous lupus erythematosus.

For further information please contact:

Henrik Moltke,

CFO

Tel: +45 39 15 77 00

Email: hkm@astion.com

Or visit: www.astion.com

Home > News & Events > News > Astion Pharma Raises EUR 5 Million in New Capital
Last updated: 2007-03-22

The official Medicon Valley site is brought to you by the organisations Region Skåne and Copenhagen Capacity - in association with Medicon Valley Alliance

Contact:
Copenhagen Capacity,	tel: +45 33 22 02 22
Region Skåne,	tel: +46 (0)40 623 97 48

ASTION PHARMA A/S

ASTION PHARMA A/S

The vision of Astion Pharma is to become a leading speciality pharmaceutical company in the field of dermatology by providing innovative anti-inflammatory drugs.